中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
Sustainability
Join us

5,000+

Staff

14.2%

2017-2019 Net Profit CAGR

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

News

Achieving Quality Sleep and improving Daytime Function – Daridorexant Launch Celebrated at the 2025 China Sleep Medicine Development Forum

On September 21, the "2025 China Sleep Medicine Development Forum," hosted by the Chinese Sleep Research Society, was held simultaneously ac...

2025-09-23
New-generation anti-insomnia drug Daridorexant issues China's first prescription, ushering in a new era of scientific sleep

On September 5, 2025, Daridorexant, a new-generation global anti-insomnia drug, successfully received the first national prescription at Xuanwu Hospit...

2025-09-05
New Drug Application (NDA) for Pediatric Influenza Antiviral Innovative Drug Deunoxavir Marboxil

On September 2, 2025, Simcere Pharmaceutical Group (2096.HK) announced that the New Drug Application (NDA) for the domestically pioneered pediatric an...

2025-09-05
New Sleep Medication Significantly Improves Multiple Sleep Parameters: Phase III Clinical Data of Daridorexant in China Published in SLEEP

On July 25, 2025, Simcere Pharmaceutical Group (2096.HK) announced that the results of the Chinese Phase III clinical trial of QUVIVIQ® (Darid...

2025-09-05

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.